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amount of rFVIIa used to achieve haemostasis. A Generalized Linear Regression
Model was used to derive the potential cost-offsets of a novel treatment. The net
monetary benefit per bleeding treated of the novel treatment compared to rFVIIa
was estimated using a variety of assumptions on the efficacy of the novel treat-
ment as well as on the valuation of the health benefits. RESULTS: Assuming a
reduction in time to bleeding resolution by 25%, a novel treatment saved €339 per
bleeding compared to rFVIIa. Including the value of the health benefits, whichwere
estimated to €51, the net monetary benefit of the novel treatment was €390 per
bleeding. The results were sensitive to assumptions around the efficacy of the new
treatment but also around the valuation of health benefits.CONCLUSIONS:Anovel
treatment which reduces time to bleeding resolution would entail important
health economic benefits, both in terms of health care cost-offsets and health
benefits. One limitation of cost-effectiveness analyses in hemophilia is the uncer-
tainty around the valuation of short term health benefits.
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BACKGROUND:Themajority of analyses of outcomes related to fertility treatments
are conducted in datasets from fertility centers. To date there has been no estab-
lished methodology for identifying fertility protocols in payer databases.
OBJECTIVES: To identify a methodology for identifying fertility protocols in a na-
tional administrative claims database. METHODS: This retrospective descriptive
study used PharmMetrics, a national managed care dataset. Patients with at least
one prescription for a gonadotropin-releasing hormone agonist (GnRHAg) or an-
tagonist (GnRHAnt) between January 1, 1999 andMay 31, 2009 were selected. Drugs
billed with a National Drug Code were included and were identified using generic
product identifiers. Index date was set as the first pharmacy claim date for a Gn-
RHAg or GnRHAnt. Patients were excluded if no prescription record for FSH existed
in the 7 days pre-index through 60 days post-index and HCG in the 60 day post-
index period. Patients must be eligible for services for 12 months before and after
the index date, which established continuous eligibility for services. Longer eligi-
bility allows assessment of outcomes such as birth rates. The final sample con-
sisted of patientswith an embryo transfer codewithin 60 days of index. Outcome of
delivery codes served as indicators for live birth if they occurredwithin 294 days (42
weeks) after transfer date. RESULTS: Inclusion and exclusion criteria were ap-
plied to patients that had at least one prescription for GnRHAnt or GnRHAg,
resulting in some attrition of sample (880 patients with IVF). The 2-year contin-
uous eligibility requirement accounted for the largest number of patients
removed. CONCLUSIONS:Administrative claims data provide a large sample of IVF
patients, but are limited in some analyses due to a lack clinical details. The pro-
posedmethodology was able to successfully identify IVF treatment cycles and link
these to delivery outcomes for treated patients under real-world conditions.
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OBJECTIVES: Individual domains of multidomain patient-reported outcome in-
struments typically are analyzed independently, without considering inherent de-
pendency of component domains. This report presents an underused modeling
approach that accounts for correlations across time (longitudinal) and correlations
across domains of a multidomain instrument in one integrated model.METHODS:
International Index of Erectile Function (IIEF) data from a double-blind placebo-
controlled trial of fixed-dose sildenafil (50 or 100 mg) in 288 men with erectile
dysfunctionwere used. Standardmethodologywas used for the individual-domain
longitudinal model. This model was then expanded to account for relationships
among domains for the multidomain longitudinal model, performing modeling of
treatment effects on all domains simultaneously. Covariance was constructed by
taking the Kronecker product of an unstructured covariance matrix across do-
mains (modeling covariance across the domains) with an unstructured covariance
matrix across time (modeling covariance across time). Analyses were performed
with Proc Mixed using SAS v9.2. RESULTS: The model was constructed and fitted,
which integrated all IIEF domains simulataneously into one unified multidomain
longitudinal model. Treatment effects for all 5 IIEF domain scores calculated using
individual ormultidomainmodelingwere similar, reflecting the robust application
of IIEF data in this study. CONCLUSIONS: Modeling correlation structure simulta-
neously across domains of amultidomain instrument, as well as across time,more
rigorously addresses the interrelationship between domains and potentially pres-
ents a more accurate estimation of efficacy and statistical inferences. Additional
work with simulations and more empirical evidence are needed to better under-
stand the multidomain longitudinal model.
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OBJECTIVES: Efficiency in health systems is often a matter of concern and differ-
ences on the expected productivity of a given procedure might lead to inefficient
variations in the performance of such interventions. Health economics literature
has extensively revisited the topic of variations in health care using multivariate
models to predict variation across geographic regions. The clustering effect of fa-
cilities (as a functional unit), however. has not been described before. This analysis
examines the extent to which facilities explain geographic variation in health care.
METHODS: A set of individual data on all births from a Contributory-Regimen
insurer in Colombia was assessed. We performed a multilevel logistic regression
model, taking hospitals as the clustering variable. In addition, we included an
alternative variance decomposition specification to estimate the attributable effect
of geographic region on the variability across hospitals. We used a set of variables
includingmother education and income, physician fees, and complications during
pregnancy to control for in this analysis. RESULTS:Our results reveal that hospitals
account for 20% of variation on the probability of performing cesarean sections.
Geographic area only explains one-third of the variance attributable to the hospi-
tal. In addition, physician fees (0.077; SE 0.023), mother’s income (0.070; SE 0.014)
and superior education in mothers (0.299; SE 0.107). This supports the effect of
mother and physician preferences on variations. CONCLUSIONS: This paper con-
tributes to previous research by using amultilevel model approach and by defining
hospitals as cluster. We found a strong effect of hospitals on determining varia-
tions. In addition, we found how supply-side factors such as physician fees and
demand-side factors (proxies for preferences) such as mother’s education and in-
come are affecting variations across hospitals and regions. The effect of facility as
well as individual-level variables should be taken into account when researching
on variations in health care.
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OBJECTIVES: The linguistic validation and cognitive debriefing of PROs are now
well documented and routinely usedwithin the pharmaceutical industry to ensure
that the translated instruments are conceptually equivalent to their sources. In-
creasingly, new adjustments are being developed to further customize these pro-
cesses according to the special needs of the instrument and target culture. This
paper seeks to enumerate the challenges faced when debriefing questionnaires of
an embarrassing, and potentially offensive, nature and recommends the use of a
specialized methodology to make respondents more comfortable during this
process. METHODS: To establish guidelines for debriefing PROs of a sensitive na-
ture, subject feedback from previous ED questionnaire debriefing reports was ex-
amined. The subjects that expressed the most discomfort during the debriefing
process resided in India, Africa, and the Middle East. Additionally, older subjects
and subjects with lower levels of education were more likely to express reserva-
tions. For this study, we collaboratedwith translators from each of these regions to
determine a list of measures that can be taken to help ensure that subjects feel
comfortable enough to provide reliable feedback within the interview setting.
RESULTS: The goal of any cognitive debriefing session is to adequately test the
translated questionnaire while maintaining the cultural sensitivities of the target
country. Recommended considerations include: assigning an interviewer of the
same sex as the subject, performing a specialized training session with interview-
ers that reviews subjects’ boundaries and strategies for effective probing, sending
subjects an introductory note that emphasizes confidentiality prior to the inter-
view, conducting interviews via telephone rather than in-person, and debriefing
questionnaires via a web-based device. CONCLUSIONS: For some cultures, cogni-
tively debriefing PRO questionnaires of a sensitive nature places added burden on
respondents. Evidence suggests that additional considerations should be exercised
during debriefing to respect subjects’ cultural boundaries.
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OBJECTIVES: To describe reporting rates and characteristics of vaccine-associated
GBS reports in the Vaccine Adverse Event Reporting System (VAERS) over a two-
decade period.METHODS:Adverse event reports submitted to VAERS from January
1990 to November 2009 are utilized to conduct a retrospective pharmacovigilance
analysis by calculating the proportional reporting ratios (PRR) and corresponding
95% confidence intervals (CI) for vaccine-GBS event pairs. RESULTS: One thousand
and 259 reports of vaccine-associated GBS are identified for 37 vaccines. Themean
age of patients experienced GBS after vaccination was 31 years; 51% of patients
were females. Majority of the reports were for influenza (FLU) (791) and hepatitis B
(HEP) virus vaccines (103). Reports for human papillomavirus quadrivalent (HPV4),
meningococcal conjugate (MNQ), and measles/mumps/rubella (MMR) virus vac-
cines accounted for 37, 36, and 34 reports, respectively. Death, disability and hos-
pitalization among the serious GBS outcomes were correspondingly reported in 36
(2.9%), 199 (15.8%), and 963 (76.4%) reports. Most of these outcomes were in FLU
reports. The average postvaccination GBS onset delay was 3.5 weeks; ranging from
2.3weeks for FLU to 8.1weeks forMNQ. About 79% and 12% of GBS reports included
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